Literature DB >> 15218180

Loss of virus-specific CD4(+) T cells with increases in viral loads in the chronic phase after vaccine-based partial control of primary simian immunodeficiency virus replication in macaques.

Wen-Hui Lun1, Akiko Takeda2,1, Hiromi Nakamura1, Munehide Kano1, Kazuyasu Mori1, Tetsutaro Sata1, Yoshiyuki Nagai3,1, Tetsuro Matano2,1.   

Abstract

Virus-specific cellular immune responses play an important role in the control of immunodeficiency virus replication. However, preclinical trials of vaccines that induce virus-specific cellular immune responses have failed to contain simian immunodeficiency virus (SIV) replication in macaques. A defective provirus DNA vaccine system that efficiently induces virus-specific CD8(+) T-cell responses has previously been developed. The vaccinated macaques showed reduced viral loads, but failed to contain SIVmac239 replication. In this study, macaques that showed partial control of SIV replication were followed up to see if or how they lost this control in the chronic phase. Two of them showed increased viral loads about 4 or 8 months after challenge and finally developed AIDS. Analysis of SIV-specific T-cell levels by detection of SIV-specific gamma interferon (IFN-gamma) production revealed that these two macaques maintained SIV-specific CD8(+) T cells, even after loss of control, but lost SIV-specific CD4(+) T cells when plasma viral loads increased. The remaining macaque kept viral loads at low levels and maintained SIV-specific CD4(+) T cells, as well as CD8(+) T cells, for more than 3 years. Additional analysis using macaques vaccinated with a Gag-expressing Sendai virus vector also found loss of viraemia control, with loss of SIV-specific CD4(+) T cells in the chronic phase of SIV infection. Thus, SIV-specific CD4(+) T cells that were able to produce IFN-gamma in response to SIV antigens were preserved by the vaccine-based partial control of primary SIV replication, but were lost with abrogation of control in the chronic phase.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15218180     DOI: 10.1099/vir.0.79890-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

1.  Urine Proteomics and Renal Single-Cell Transcriptomics Implicate Interleukin-16 in Lupus Nephritis.

Authors:  Andrea Fava; Deepak A Rao; Chandra Mohan; Ting Zhang; Avi Rosenberg; Paride Fenaroli; H Michael Belmont; Peter Izmirly; Robert Clancy; Jose Monroy Trujillo; Derek Fine; Arnon Arazi; Celine C Berthier; Anne Davidson; Judith A James; Betty Diamond; Nir Hacohen; David Wofsy; Soumya Raychaudhuri; William Apruzzese; Jill Buyon; Michelle Petri
Journal:  Arthritis Rheumatol       Date:  2022-04-16       Impact factor: 15.483

2.  Vaccine targeting SIVmac251 protease cleavage sites protects macaques against vaginal infection.

Authors:  Hongzhao Li; Robert W Omange; Binhua Liang; Nikki Toledo; Yan Hai; Lewis R Liu; Dane Schalk; Jose Crecente-Campo; Tamara G Dacoba; Andrew B Lambe; So-Yon Lim; Lin Li; Mohammad Abul Kashem; Yanmin Wan; Jorge F Correia-Pinto; Michael S Seaman; Xiao Qing Liu; Robert F Balshaw; Qingsheng Li; Nancy Schultz-Darken; Maria J Alonso; Francis A Plummer; James B Whitney; Ma Luo
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

3.  Patterns of CD8+ immunodominance may influence the ability of Mamu-B*08-positive macaques to naturally control simian immunodeficiency virus SIVmac239 replication.

Authors:  John T Loffredo; Alex T Bean; Dominic R Beal; Enrique J León; Gemma E May; Shari M Piaskowski; Jessica R Furlott; Jason Reed; Solomon K Musani; Eva G Rakasz; Thomas C Friedrich; Nancy A Wilson; David B Allison; David I Watkins
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

4.  Circumventing antivector immunity by using adenovirus-infected blood cells for repeated application of adenovirus-vectored vaccines: proof of concept in rhesus macaques.

Authors:  Caijun Sun; Liqiang Feng; Yinfeng Zhang; Lijun Xiao; Weiqi Pan; Chufang Li; Linqi Zhang; Ling Chen
Journal:  J Virol       Date:  2012-08-01       Impact factor: 5.103

5.  FIV vaccine with receptor epitopes results in neutralizing antibodies but does not confer resistance to challenge.

Authors:  Craig Miller; Mauren Emanuelli; Elizabeth Fink; Esther Musselman; Ryan Mackie; Ryan Troyer; John Elder; Sue VandeWoude
Journal:  NPJ Vaccines       Date:  2018-04-30       Impact factor: 7.344

Review 6.  Applications of the FIV Model to Study HIV Pathogenesis.

Authors:  Craig Miller; Zaid Abdo; Aaron Ericsson; John Elder; Sue VandeWoude
Journal:  Viruses       Date:  2018-04-20       Impact factor: 5.048

Review 7.  Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development.

Authors:  Julie Bigay; Roger Le Grand; Frédéric Martinon; Pauline Maisonnasse
Journal:  Front Microbiol       Date:  2022-08-10       Impact factor: 6.064

Review 8.  Vaccine-induced enhancement of viral infections.

Authors:  W Huisman; B E E Martina; G F Rimmelzwaan; R A Gruters; A D M E Osterhaus
Journal:  Vaccine       Date:  2008-11-18       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.